C4 Therapeutics Inc

NASDAQ:CCCC   1:55:37 PM EDT
7.07
+0.26 (+3.82%)
Earnings Announcements

C4 Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/05/2022 12:53 GMT
C4 Therapeutics Inc (CCCC) - C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights.
C4 Therapeutics - Cash, Cash Equivalents and Marketable Securities Total $421.7 Million As of March 31, 2022; Expected to Provide Runway to End of 2024.
Total Revenue for Q1 of 2022 Was $7.7 Million, Compared to $7.4 Million for Q1 of 2021.
Net Loss per Share for Q1 of 2022 Was $0.65.
Q1 Earnings per Share View $-0.58, Revenue View $8.1 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $7.95 Million
Adjusted EPS is expected to be -$0.69

Next Quarter Revenue Guidance is expected to be $8.01 Million
Next Quarter EPS Guidance is expected to be -$0.73

More details on our Analysts Page.